Company overview
Basic information
Company name
DNA Studija, MB
Company code
304292551
VAT code
LT100013091512
Registered address
Vilnius, Šv. Stepono g. 38-20, LT-01312
Registration date
2016-07-05
Company age: 10 y. 3 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Website
https://dnastudio.lt
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Architectural activities
Ownership form
Private without foreign capital
MB DNA Studija
Company code: 304292551
Address: Vilnius, Šv. Stepono g. 38-20, LT-01312
VAT code: LT100013091512
Description
This description was generated by artificial intelligence.
DNA Studija, MB (company code 304292551) is an operational private small partnership registered on 5 July 2016. The company is part of the national private non-financial companies sector and is classified as privately owned, with more than 50% of authorised capital held by Lithuanian natural and legal persons and no foreign investor capital. Governance is listed as CEO only, and the company is classified as micro. It is based in Vilnius, at Šv. Stepono g. 38-20, Vilnius city municipality, Vilnius County. Its main activity is EVRK N.71.11.00, Architectural activities.
Financially, the company has shown steady growth in recent years. Revenue increased from €134.2K in 2023 to €169.0K in 2024 and €200.7K in 2025, with year-on-year growth of 18.7% in 2025 and 49.6% over two years. Net profit improved from a loss of €1.2K in 2023 to a profit of €604 in 2024 and €2.2K in 2025. The 2025 profit margin was 1.1%. At the end of 2025, equity stood at €10.2K, total assets at €100.5K and liabilities at €90.4K. Staff reporting is tracked so far in 2026.
Financially, the company has shown steady growth in recent years. Revenue increased from €134.2K in 2023 to €169.0K in 2024 and €200.7K in 2025, with year-on-year growth of 18.7% in 2025 and 49.6% over two years. Net profit improved from a loss of €1.2K in 2023 to a profit of €604 in 2024 and €2.2K in 2025. The 2025 profit margin was 1.1%. At the end of 2025, equity stood at €10.2K, total assets at €100.5K and liabilities at €90.4K. Staff reporting is tracked so far in 2026.
Download a detailed company report
Make confident decisions with all the information about DNA Studija, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.